DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation

Phase 1

Terminated

Conditions: Non-cystic Fibrosis Bronchiectasis

Interventions: Drug: BI 1323495
Drug: Placebo

First Posted Date: 2020-12-07

Last Posted Date: 2024-11-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT04656275

Locations: 🇩🇪
IKF Pneumologie GmbH & Co. KG, Frankfurt, Germany
🇩🇪
Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, Germany
🇩🇪
KLB Gesundheitsforschung Lübeck GmbH, Lübeck, Germany

A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 764198 - Formula C
Drug: BI 764198 - Formula D
Drug: BI 764198 - Formula B
Drug: BI 764198 - Formula A

First Posted Date: 2020-12-07

Last Posted Date: 2021-03-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT04656288

Locations: 🇧🇪
SGS Belgium NV Research Unit Stuivenberg, Antwerpen, Belgium

A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: BI 765063
Drug: BI 754091

First Posted Date: 2020-12-04

Last Posted Date: 2022-05-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT04653142

Locations: 🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan
🇯🇵
National Cancer Center Hospital, Tokyo, Chuo-ku, Japan
🇯🇵
Shikoku Cancer Center, Ehime, Matsuyama, Japan

and more 1 locations

A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19

Phase 2

Completed

Conditions: Acute Respiratory Distress Syndrome

Interventions: Procedure: Standard of care
Drug: Alteplase low dose
Drug: Alteplase high dose

First Posted Date: 2020-11-23

Last Posted Date: 2024-03-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 104

Registration Number: NCT04640194

Locations: 🇩🇪
Petrus-Krankenhaus, Wuppertal, Germany
🇪🇸
Hospital Puerta del Mar, Cádiz, Spain
🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain

and more 34 locations

A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation

Phase 1

Terminated

Conditions: Metastatic Colorectal Cancer (CRC)

Interventions: Drug: BI 1701963
Drug: Camptosar®

First Posted Date: 2020-11-13

Last Posted Date: 2022-04-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT04627142

Locations: 🇨🇳
Shanghai East Hospital, Tongji University China, Shanghai, China

A Study in Healthy Japanese Men to Test How Different Doses of BI 1323495 Are Tolerated and How Itraconazole Influences the Amount of BI 1323495 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1323495
Drug: Placebo
Drug: Itraconazole

First Posted Date: 2020-11-06

Last Posted Date: 2024-03-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 74

Registration Number: NCT04619251

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib

Active, not recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: OFEV®

First Posted Date: 2020-11-04

Last Posted Date: 2025-01-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 214

Registration Number: NCT04614441

Locations: 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
🇨🇳
E-Da Hospital, Kaohsiung, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

and more 24 locations

ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: BI 764198

First Posted Date: 2020-10-27

Last Posted Date: 2022-04-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 133

Registration Number: NCT04604184

Locations: 🇧🇷
Hospital Regional Hans Dieter Schmidt, Santa Catarina, Brazil
🇲🇽
Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico
🇺🇸
St. Elizabeth's Medical Center, Boston, Massachusetts, United States

and more 22 locations

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lamotrigine
Drug: BI 409306
Drug: Placebo
Drug: BI 425809

First Posted Date: 2020-10-26

Last Posted Date: 2024-03-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT04602221

Locations: 🇺🇸
Hassman Research Institute, Marlton, New Jersey, United States
🇺🇸
Collaborative Neuroscience Research, LLC, Long Beach, California, United States

COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With Salivette® Cortisol for Viral RNA Sampling for RT-qPCR

Not Applicable

Completed

Conditions: Covid-19

Interventions: Diagnostic Test: Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol

First Posted Date: 2020-10-23

Last Posted Date: 2021-07-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 151

Registration Number: NCT04599959

Locations: 🇲🇽
Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy